| Beverage Maker Adopts Health to Wealth Principle With Innovative Launch |
|
| From PepsiCo's innovative push into health-conscious beverages to Charles Schwab's robust buyback program and First Financial Bancorp's impressive earnings growth, this roundup highlights key players making strategic moves.
Plus, we cover recent dividend changes, upcoming payouts, and market developments shaping the investment landscape today. |
|
| | | | Before Buzz (Sponsored) | | | The market loves to chase the buzz.
But the real money is made before the hype begins. | That's what makes this free report so useful — it features five small-cap companies quietly building value while remaining off the radar of large institutions. | The business models are strong.
The data is compelling.
And the window to act is still open. | If you like spotting real potential before it's obvious, don't miss this.
[Download the Report Free Now]
(By clicking the link above you agree to receive emails from us and our affiliates. You can opt out at any time - Privacy Policy) |
|
| | Healthcare | Kimberly-Clark Exits IFP Segment in $1.7B Joint Venture With Suzano | | Kimberly-Clark (NYSE: KMB) is restructuring its global footprint by forming a $1.7 billion joint venture with Brazilian pulp giant Suzano S.A., which will effectively exit its International Family Care and Professional (IFP) segment. | Suzano will acquire a controlling 51% stake, while Kimberly-Clark retains 49%. The move signals a shift in focus away from certain emerging-market operations and toward its core personal care and tissue businesses. | For long-term shareholders, this deal suggests a strategic pivot away from lower-margin or complex markets, and toward improved capital allocation and operational clarity. By partnering with Suzano, Kimberly-Clark offloads asset complexity while retaining upside through its minority stake. | Those evaluating a new position in KMB may find this move aligns with a cleaner, more focused corporate structure. The company is signaling discipline in segment management, and this realignment may support stronger margin profiles over time, especially if reinvested capital boosts core brand growth or innovation. | The real test will come in execution, but structurally, Kimberly-Clark is signaling that it's ready to run leaner, more deliberately, and with sharper geographic discipline. The shift also sets a baseline for investors to track margin improvement and potential reinvestment outcomes as the company adapts its global playbook. | (KMB currently trades at $127 and pays a dividend of $5.04 per share, a yield of 3.98%.) |
|
| | Retail | Walmart Makes Vizio Exclusive, Pulls Brand from Amazon and Target | | Walmart (NYSE: WMT) is turning Vizio into an exclusive in-house brand, removing the popular electronics label from competing retailers like Amazon, Target, and Best Buy. After acquiring Vizio for $2.38 billion in December 2024, Walmart has confirmed that the brand will be sold exclusively through Walmart and Sam's Club as it integrates Vizio under its expanding private-label strategy. | The rollout is more than a distribution change. Walmart plans to integrate Vizio's SmartCast software into its broader electronics offerings, including cross-functionality with its Onn brand and a new interface that allows customers to shop directly through their TVs. | For long-term shareholders, this shift reinforces Walmart's multi-channel strategy and strengthens its digital monetization potential. By pulling Vizio off rival shelves, the company is prioritizing exclusivity and platform control, which are key levers in protecting retail margins and deepening customer stickiness. | Integrating SmartCast could give Walmart a competitive edge in gathering user data and promoting its internal brands. This move would eventually generate advertising revenue through connected TV features. | The Vizio exclusivity push gives Walmart a firmer grip on the fast-growing smart home market. By controlling both the devices and the software layer, Walmart is building a retail ecosystem that reaches far beyond the store aisle. | (WMT currently trades at $97 and pays a dividend of $0.94 per share, a yield of 0.96%.) |
|
| | Hidden Shot (Sponsored) | | | The secret to finding big moves that could end up like the ones below is knowing where to look: | Triller Group Inc (ILLR): From $.66 to $8.86 (+1,242%) | Quantum Computing Inc (QUBT): From $.35 to $4.69 (+1,240%) | Eco Wave Power (WAVE): From $1.01 to $12.39 (+1,126%) | The choice is yours: You can do nothing, and you'll end up on the sidelines for the next +1,200% move. Or you can take action… | Not long from now, Market Pulse Today will reveal its first alert of the quarter—a company with serious breakout potential. | The best part? | It's 100% free. | [Click Here to Get the Alert First] | You can make it happen or wonder "What happened?"
(By clicking the link above, you agree to receive emails from Market Pulse. You can opt out at any time. - Privacy Policy) |
|
| | Oncology | Pfizer Commits $1.25B to Acquire Global Rights for Next-Gen Cancer Antibody | | Pfizer (NYSE: PFE) has expanded its oncology pipeline through a $1.25 billion global licensing agreement with 3SBio, acquiring exclusive rights to the bispecific antibody SSGJ-707 outside of China. The deal also includes a $100 million equity investment and leaves open the option for Pfizer to extend those rights to the Chinese market for an additional $150 million. | SSGJ-707 targets PD-1 and VEGF, two critical pathways in cancer treatment, and has already shown promising Phase II results in China for non-small cell lung cancer. Pfizer will manufacture the drug substance in North Carolina and oversee global clinical development, including new trials conducted across the U.S. and at other international sites, with a focus on solid tumors. | For long-term shareholders, the agreement strengthens Pfizer's positioning in next-generation immuno-oncology therapies. Rather than relying solely on in-house R&D, the company is leveraging external innovation to fill pipeline gaps in high-impact cancer indications. | Those looking into Pfizer should see this deal as more than portfolio padding. It aligns with a broader capital deployment strategy that prioritizes scalable cancer treatments with multi-market potential. The planned Phase III development path also aligns with Pfizer's shift toward specialized therapeutics beyond traditional blockbusters. | SSGJ-707 provides Pfizer with a fresh asset, boasting global ambitions, early clinical momentum, and room to build combination strategies. As trial results emerge, this could become a foundational component in the company's oncology expansion. | (PFE currently trades at $25 and pays a dividend of $1.72 per share, a yield of 6.96%.) |
|
| | Dividend Stocks Worth Watching | PepsiCo, Inc (NYSE: PEP) stock is down 5.07% on the year to date but could tapping into the 'health is wealth' mindset see the beverage maker turnaround its fortunes? | The soda maker is targeting revenue improvement after a lackluster start to the year. As part of those efforts, it will shut down manufacturing, transport and maintenance operations at its Detroit site and has announced plans to create the first ever prebiotic cola drink. | Pepsi Prebiotic Cola will go on sale at the beginning of next year and will give consumers three grams of prebiotic fiber per can. This could be a savvy move for PEP, as wider consumer trends suggest a move away from traditional sodas towards healthier alternatives. PEP stock currently offers investors a solid 9.7% yield and a $1.422 dividend payout. | Charles Schwab (NYSE: SCHW) is a multinational financial services company with a wide range of trading products, accounts and investment products. Its board has just authorized a new $20 billion stock repurchase program, replacing the previous authorization. Co-Chairman Walt Bettinger said the program reflected broader confidence in business momentum as it focuses on growth – the stock is up 30% on the year to date. | SCHW currently offers investors a 1.12% yield. | First Financial Bancorp (NYSE: FFBC) has been providing banking services for more than 160 years across Ohio, Kentucky, Indiana, and Illinois. The company offers a dividend yield above 4%, supported by sound fundamentals and net interest margin expansion. | Earlier this week FFBC published its Q2 results, with double-digit earnings growth and improved margins helping to boost investor confidence. It pays a 24 cents dividend with a 3.88% yield. | | Dividend Increases | | | AROC has increased its quarterly dividend payment to 21 cents per share, an increase of 10.53%. Its new yield is 3.59%. | FIX has raised its quarterly dividend payment to 50 cents per share, an increase of 11.11%. Its new yield is 0.36%. | Southern Missouri Bancorp raised its dividend payment to 25 cents per share, an increase of 8.70%. Its new yield is 1.6%. |
| |
|
| Dividend Decreases | | | | | DMLP has decreased its dividend payment to 62 cents per share, a drop of 14.55%. The new yield is 9.03%. | TIMB has reduced its dividend payment to 12 cents per share, a cut of 14.67%. Its new yield is 7.2%. | DOW has slashed its dividend payout to 35 cents per share, a decline of 50%. The yield is now 4.6%. |
| |
| | |
| | | | Upcoming Dividend Payers | TNET's ex-dividend date for the upcoming 28 cents payout is 07/28/25. | BKE's ex-dividend date for the upcoming 35 cents payout is 07/29/25. | TWO's ex-dividend date for the upcoming 39 cents payout is 07/29/25. | | | | That's all for today's edition of the Dividend Brief.
Thanks for reading, and if you have any feedback or dividend stocks you want me to take a look at, just reply to this email!
—Noah Zelvis
DividendBrief.com |
|
